β3-AR agonist 1 manufacturers
- β3-AR agonist 1
-
- $1970.00
-
2026-04-20
- CAS:1283125-73-4
- Purity:
- Supply Ability: 10g
- β3-AR agonist 1
-
- $1970.00
-
2025-10-28
- CAS:1283125-73-4
- Purity:
- Supply Ability: 10g
|
| | β3-AR agonist 1 Basic information |
| Product Name: | β3-AR agonist 1 | | Synonyms: | β3-AR agonist 1;Cyclobutanesulfonamide, N-[3-[(1R)-1-hydroxy-2-[[2-[(3-methyl-1H-indazol-6-yl)oxy]ethyl]amino]ethyl]phenyl]-;β3 AR agonist 1,β3AR agonist 1 | | CAS: | 1283125-73-4 | | MF: | C22H28N4O4S | | MW: | 444.55 | | EINECS: | | | Product Categories: | | | Mol File: | 1283125-73-4.mol |  |
| | β3-AR agonist 1 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO |
| | β3-AR agonist 1 Usage And Synthesis |
| Description | β3-AR agonist 1 (compound 15) is a highly potent, selective, and orally available β3-adrenergic receptor (β3-AR) agonist (EC50=18 nM), being inactive to β1-, β2-, and α1A-AR (β1/β3, β2/β3, and α1A/β3>556-fold)[1].
EC50: 18 nM (β3-AR)[1] β3-AR agonist 1 (compound 15) shows dose-dependent β3-AR-mediated responses in marmoset urinary bladder smooth muscle, has a desirable metabolic stability and pharmacokinetic profile (Cmax and AUC), and do not obviously affect heart rate or mean blood pressure when administered intravenously (3 mg/kg) to anesthetized rats[1]. | | Uses | β3-AR agonist 1 (compound 15) is a highly potent, selective, and orally available β3-adrenergic receptor (β3-AR) agonist (EC50=18 nM), being inactive to β1-, β2-, and α1A-AR (β1/β3, β2/β3, and α1A/β3>556-fold)[1]. | | in vivo | β3-AR agonist 1 (compound 15) shows dose-dependent β3-AR-mediated responses in marmoset urinary bladder smooth muscle, has a desirable metabolic stability and pharmacokinetic profile (Cmax and AUC), and do not obviously affect heart rate or mean blood pressure when administered intravenously (3 mg/kg) to anesthetized rats[1]. | | References | [1]. Wada Y, et al. Discovery of Novel Indazole Derivatives as Orally Available β3-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects. J Med Chem. 2017 Apr 27;60(8):3252-3265. |
| | β3-AR agonist 1 Preparation Products And Raw materials |
|